Boehringer Expands Eyecare Horizons With Palatin Collaboration

Around half of patients taking anti-VEGF therapies still have fluid on the eye, compromising their vision. • Source: Image archive
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business